Last reviewed · How we verify
Travoprost and Timolol
Travoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor, while timolol is a non-selective beta-blocker that decreases aqueous humor production, together reducing intraocular pressure.
Travoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor, while timolol is a non-selective beta-blocker that decreases aqueous humor production, together reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Travoprost and Timolol |
|---|---|
| Also known as | Travoprost 0.004%/timolol 0.5% fixed combination |
| Sponsor | Afyon Kocatepe University Hospital |
| Drug class | Prostaglandin analog and beta-blocker combination |
| Target | FP receptor (travoprost); beta-2 adrenergic receptor (timolol) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Travoprost binds to prostaglandin F (FP) receptors on the ciliary muscle and trabecular meshwork, enhancing drainage of aqueous humor through the uveoscleral pathway. Timolol blocks beta-2 adrenergic receptors in the ciliary body, reducing aqueous humor secretion. The combination provides additive intraocular pressure-lowering effects through complementary mechanisms.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation/discomfort
- Increased iris pigmentation
- Eyelash growth
- Bradycardia (systemic)
- Fatigue
Key clinical trials
- Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE2, PHASE3)
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution (PHASE2)
- Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
- Interval Intraocular Pressure in Intravitreal Injection Study (NA)
- Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Travoprost and Timolol CI brief — competitive landscape report
- Travoprost and Timolol updates RSS · CI watch RSS
- Afyon Kocatepe University Hospital portfolio CI